Q-omics provides the consensus-scored NFKBIA profile across patient tissues and cancer cell-line models. NFKBIA expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NFKBIA is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NFKBIA protein abundance shows 22,319 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, KIRC, and PDAC as cancer lineages where NFKBIA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFKBIA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFKBIA survival associations across molecular data types. NFKBIA RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFKBIA RNA expression–survival associations across cancer types. High NFKBIA expression shows unfavorable associations in UVM and LAML, but favorable associations in SKCM, BRCA, MESO and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for NFKBIA RNA expression.
This table summarizes NFKBIA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NFKBIA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFKBIA shows lower tumor expression in KICH, LUSC, LUAD and BLCA and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher NFKBIA RNA expression in tumor versus normal tissue (log2 FC = +0.641, t-test p < 0.001).
This table shows molecular features associated with NFKBIA in patient tissues and cancer cell lines. In patient samples, NFKBIA shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, NFKBIA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
